The Need for Rapid Cytogenetics in the Era of Unique Therapies For acute Myeloid Leukemia

Overview

Journal Blood Adv

Specialty Hematology

Date 2022 Aug 16

PMID 35973157

Authors

Anjanaa Vijayanarayanan

Brandon M Shaw

Kathryn Gibbons

Kedar V Inamdar

Philip Kuriakose

Madhu P Menon

Affiliations

Soon will be listed here.

Citing Articles

Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.

Hochman M, Muniz J, Papadantonakis N J Pers Med. 2025; 15(2).

PMID: 39997326 PMC: 11856194. DOI: 10.3390/jpm15020049.

References

Rozman M, Navarro J, Arenillas L, Aventin A, Gimenez T, Alonso E . Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. Ann Hematol. 2014; 93(10):1695-703. DOI: 10.1007/s00277-014-2100-6. View

Bacher U, Schnittger S, Macijewski K, Grossmann V, Kohlmann A, Alpermann T . Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Blood. 2012; 119(20):4719-22. DOI: 10.1182/blood-2011-12-395574. View

Krauss A, Gao X, Li L, Manning M, Patel P, Fu W . FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2018; 25(9):2685-2690. DOI: 10.1158/1078-0432.CCR-18-2990. View

Mikhail F, Heerema N, Rao K, Burnside R, Cherry A, Cooley L . Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities. Genet Med. 2016; 18(6):635-42. DOI: 10.1038/gim.2016.50. View

Ostgard L, Medeiros B, Sengelov H, Norgaard M, Klarskov Andersen M, Dufva I . Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol. 2015; 33(31):3641-9. DOI: 10.1200/JCO.2014.60.0890. View

Mantere T, Neveling K, Pebrel-Richard C, Benoist M, van der Zande G, Kater-Baats E . Optical genome mapping enables constitutional chromosomal aberration detection. Am J Hum Genet. 2021; 108(8):1409-1422. PMC: 8387289. DOI: 10.1016/j.ajhg.2021.05.012. View

Arber D, Erba H . Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020; 154(6):731-741. PMC: 7610263. DOI: 10.1093/ajcp/aqaa107. View

Hulegardh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf A . Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2014; 90(3):208-14. DOI: 10.1002/ajh.23908. View

Ohgami R, Arber D . Challenges in Consolidated Reporting of Hematopoietic Neoplasms. Surg Pathol Clin. 2016; 6(4):795-806. DOI: 10.1016/j.path.2013.08.001. View

10.

Borthakur G, Kantarjian H . Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021; 11(6):114. PMC: 8209225. DOI: 10.1038/s41408-021-00503-6. View

11.

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

12.

Jen E, Ko C, Lee J, Del Valle P, Aydanian A, Jewell C . FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia. Clin Cancer Res. 2018; 24(14):3242-3246. DOI: 10.1158/1078-0432.CCR-17-3179. View

13.

Diaz-Beya M, Rozman M, Pratcorona M, Torrebadell M, Camos M, Aguilar J . The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. Blood. 2010; 116(26):6147-8. DOI: 10.1182/blood-2010-09-307314. View

14.

Duncavage E, Schroeder M, OLaughlin M, Wilson R, MacMillan S, Bohannon A . Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. N Engl J Med. 2021; 384(10):924-935. PMC: 8130455. DOI: 10.1056/NEJMoa2024534. View